REFERENCES
  1. Larsen FS, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am. 2002;22(1):1–24.
  2. Beltrani VS, Boguneiwicz M. Atopic dermatitis. Dermatol Online J. 2003;9(2):1–27.
  3. Eichenfield LF, Lucky AW, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495–504.
  4. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Handout on health: Atopic dermatitis. Available at: www.niams.nih.gov/Health_Info/Atopic_Dermatitis/default.asp. Accessed March 2, 2012.
  5. Hanifin JM, Cooper KD, et al. Guidelines of care for atopic dermatitis. J Am Acad Dermatol. 2004;50:391–404.
  6. ELIDEL [package insert]. Bridgewater, NJ; Valeant Pharmaceuticals, North America, LLC.
  7. Wahn U, Bos JD, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1). Available at: www.pediatrics.org/cgi/content/full/110/1/e2.
  8. Wellington K, Noble S. Pimecrolimus: A review of its use in atopic dermatitis. Am J Clin Dermatol. 2004;5(6):480–495.
  9. Murrell DF, Calvieri S, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol. 2007;157:954–959.
  10. Data on file (ELIDEL safety revisited: recently compiled data). Coria Laboratories, a division of Valeant Pharmaceuticals North America LLC; Bridgewater, NJ.
See More

INDICATION

ELIDEL® (pimecrolimus) Cream 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable.


IMPORTANT SAFETY INFORMATION

WARNING:

Long-term Safety of Topical Calcineurin Inhibitors Has Not Been Established. Although a causal relationship has not been established, rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including ELIDEL Cream.